Sarah Ketterer
Causeway Capital Management
Sarah Ketterer Bristol-Myers Squibb Company stake
total: 372
Causeway Capital Management BMY trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2024 Q2
- Held for:
- 2 quarters
- Latest activity:
- 2024 Q4
According to 2026 Q2 report, Sarah Ketterer doesn't hold any Bristol-Myers Squibb Company (BMY) shares. To date, the estimated cost basis is nearly $41.84 for "buy" trades and estimated average "sell" price is $51.74. Causeway Capital Management first purchased BMY in 2024 Q2, initially acquiring 727,352 shares. Since the initial investment in Bristol-Myers Squibb Company (BMY), Causeway Capital Management has made 2 more transactions.
When did Sarah Ketterer sell Bristol-Myers Squibb Company (BMY)?
Sarah Ketterer sold off the entire Bristol-Myers Squibb Company (BMY) position in 2024 Q4.
When did Sarah Ketterer buy Bristol-Myers Squibb Company (BMY)?
Sarah Ketterer first invested in Bristol-Myers Squibb Company (BMY) in 2024 Q2 at the reported quarter-end price of $41.53 per share.
What's the cost basis of Causeway Capital Management's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $41.84 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $41.84
- Weighted AVG sell price:
- $51.74
Sarah Ketterer's historical trades in Bristol-Myers Squibb Company
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.00%
|
0
|
$51.74
|
|
-100% (-750,455)
|
-0.95%
|
|
2024 Q3
|
0.95%
|
750,455
|
$51.74
|
$38,828,510
|
+3.18% (+23,103)
|
+0.03%
|
|
2024 Q2
|
0.82%
|
727,352
|
$41.53
|
$30,206,934
|
new
|
+0.82%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.